SOLUBLE ENDOGLIN LEVELS AS A MARKER OF CEREBROVASCULAR DISORDERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Notice bibliographique
Résumé
PV047 / #805 Poster Topic: AS05 - CNS Lupus Background/Purpose Cerebrovascular manifestations in patients with systemic lupus erythematosus (SLE) are quite frequent and diverse. Their prevalence ranges from 12% to 95%. Recently, the attention of scientists has been drawn to the biomolecule endoglin (ENG) associated with the pathogenesis of certain neurological and autoimmune diseases. The role of soluble endoglin (sol-endoglin) as an antiangiogenic agent has been studied in various diseases. However, no information has been found on the levels of sol-endoglin in the serum of SLE patients. Our goal is to study the level of sol-endoglin in SLE patients and assess its relationship with lesions of the central and peripheral nervous system, as well as some indicators of mental health. Methods 96 SLE patients aged 19 to 55 years were examined, 7 (7.3%) men and 89 (92.7%) women, mean disease duration was 6.2±0.4 years, mean age was 37.5±0.9 years and 20 people in the control group with a mean age of 39.0±1.09. To assess the neurological status, the following were used: Zung Depression Scale, Spielberger Anxiety Scale, Montreal Cognitive Assessment Scale (MCA), visual and auditory memory tests. The content of endoglin in blood serum was determined by ELISA. Results In SLE patients, the level of endoglin was significantly higher by 90.4% (p<0.001) compared to the control group. Thus, in the control group, the level of endoglin fluctuated in the range of 1.14-2.56 ng/ml (95% CI) with a median of 1.86 ng/ml, and in SLE patients the level of endoglin fluctuated in the range of 1.58-6.53 (95% CI) with a median of 3.28 ng/ml. In order to assess the relationship between endoglin levels and the characteristics of the patient’s psychoneurological condition, all SLE patients were divided into 4 subgroups depending on the level of endoglin: the 1st quartile (Q1) included 24 individuals with an endoglin level <2.55 ng/ml; 2nd quartile (Q2) – 25 people with endoglin levels of 2.55-3.28 ng/ml; 3rd quartile (Q3) – 23 people with levels of 3.29 – 4.24 ng/ml; 4th quartile (Q4) – 24 people with levels of >4.24 ng/ml. From the 1st to the 4th quartile, an increase in the proportion of patients with nervous system damage was observed. In group Q4, the proportion of people with CNS damage was significantly higher by 3.28 times (p<0.05) than in group Q1. The proportion of patients with peripheral nervous system damage in Q3 and Q4 exceeded 50% and was higher by 2.99-3.38 times (p<0.05) than among patients with endoglin levels less than 2.55 ng/ml. Analysis of mental health indicators of SLE patients depending on the quartile distribution of endoglin levels showed that almost all of the studied mental health indicators of patients significantly worsened from the 1st to the 4th quartile. Thus, in the Q4 group, the proportion of patients with verified anxiety, depressive disorders, and cognitive dysfunction was statistically significantly higher by 2.4; 5.52 and 2.74 times (p<0.05) than in the Q1 group. A high frequency of memory disorders and sleep disorders was recorded in all quartile groups (without statistically significant intergroup differences). Conclusions Thus, serum endoglin levels in SLE patients with SLE are significantly higher than in the control group. Increased serum endoglin levels were associated with worsening mental health indicators in SLE patients, and namely a significant increase in the proportion of individuals with significant anxiety, depressive, and cognitive disorders, as well as insomnia.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».